Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human (ICAST)
This study has been completed.
Sponsor:
innoVactiv Inc.
Information provided by:
innoVactiv Inc.
ClinicalTrials.gov Identifier:
NCT00936754
First received: July 9, 2009
Last updated: January 18, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary endpoint of this trial will be to evaluate the safety of a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder when taken 30 minutes before a test meal. The secondary endpoint of this trial will be to evaluate if a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder is able to reduce the rate of carbohydrate absorption as measured by following postprandial glycemia and insulinemia.
| Condition | Intervention | Phase |
|---|---|---|
|
Glycemic Index |
Dietary Supplement: Brown seaweed powder Dietary Supplement: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | Safety and Efficacy of a Unique Dose of a Brown Seaweeds Powder Enriched in Polyphenols on Human |
Further study details as provided by innoVactiv Inc.:
Primary Outcome Measures:
- Safety of a single 500 mg administration of a brown seaweed extract in human [ Time Frame: First administration up to 7 days after last administration ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Significant reduction of glycemic index of test food [ Time Frame: Immediately after product administration (single use) ] [ Designated as safety issue: No ]
- Significant reduction in postprandial glycemia [ Time Frame: Immediately after product administration (single use) ] [ Designated as safety issue: No ]
- Significant reduction in postprandial insulinemia [ Time Frame: Immediately after product administration (single use) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 23 |
| Study Start Date: | July 2009 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment
Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
|
Dietary Supplement: Brown seaweed powder
500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
|
|
Placebo Comparator: Placebo
Single administration of encapsulated placebo, taken 30 minutes before test meal
|
Dietary Supplement: Placebo
Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy volunteer
- BMI between 20 and 30
- Non-smoking
Exclusion Criteria:
- Iodine allergy
- Diabetes
- Use of dietary supplements for duration of study
- History of major surgeries or surgeries of the stomach or digestive tract
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00936754
Locations
| Canada | |
| Institut des Nutraceutiques et des Aliments Fonctionnels (INAF) | |
| Quebec, Canada, G1V 0A6 | |
Sponsors and Collaborators
innoVactiv Inc.
Investigators
| Principal Investigator: | Patrick Couture, MD, PhD | Institut des nutraceutiques et des aliments fonctionnels |
More Information
No publications provided
| Responsible Party: | Jocelyn Bérubé/Scientific Director, Health & Nutrition, innoVactiv inc. |
| ClinicalTrials.gov Identifier: | NCT00936754 History of Changes |
| Other Study ID Numbers: | 2005-RD-10-CLN2 |
| Study First Received: | July 9, 2009 |
| Last Updated: | January 18, 2010 |
| Health Authority: | Canada: Health Canada |
Keywords provided by innoVactiv Inc.:
|
Glycemic index Reduction of glycemic index of ingested foods |
ClinicalTrials.gov processed this record on May 21, 2013